RxSight (RXST) Competitors $13.22 +0.10 (+0.72%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, AORT, and LQDAShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), Artivion (AORT), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Tandem Diabetes Care SS Innovations International Cadre Artivion Liquidia Technologies RxSight (NASDAQ:RXST) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Which has more volatility & risk, RXST or NVCR? RxSight has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Is RXST or NVCR more profitable? RxSight has a net margin of -17.90% compared to NovoCure's net margin of -26.41%. RxSight's return on equity of -9.54% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-17.90% -9.54% -8.51% NovoCure -26.41%-45.46%-13.34% Does the media favor RXST or NVCR? In the previous week, NovoCure had 9 more articles in the media than RxSight. MarketBeat recorded 11 mentions for NovoCure and 2 mentions for RxSight. RxSight's average media sentiment score of 0.94 beat NovoCure's score of 0.52 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RXST or NVCR? RxSight currently has a consensus price target of $37.90, indicating a potential upside of 186.80%. NovoCure has a consensus price target of $32.83, indicating a potential upside of 82.31%. Given RxSight's higher probable upside, analysts plainly believe RxSight is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.30NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders believe in RXST or NVCR? 78.8% of RxSight shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, RXST or NVCR? RxSight has higher earnings, but lower revenue than NovoCure. RxSight is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M3.84-$27.45M-$0.67-19.72NovoCure$605.22M3.32-$168.63M-$1.51-11.93 SummaryRxSight beats NovoCure on 11 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$540.31M$6.86B$5.50B$8.93BDividend YieldN/A1.04%5.38%4.12%P/E Ratio-19.8426.5326.2519.86Price / Sales3.8492.92415.14113.78Price / CashN/A21.0536.4957.06Price / Book1.894.738.055.38Net Income-$27.45M$173.18M$3.16B$248.50M7 Day Performance0.27%1.19%1.78%2.78%1 Month Performance-14.91%0.02%4.74%5.84%1 Year Performance-76.83%28.01%35.81%20.06% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight2.6622 of 5 stars$13.22+0.7%$37.90+186.8%-76.9%$540.31M$139.93M-19.84220NVCRNovoCure3.7769 of 5 stars$16.61-0.5%$32.83+97.7%+3.1%$1.86B$605.22M-11.001,488Positive NewsLMATLeMaitre Vascular2.5417 of 5 stars$83.38+2.0%$97.83+17.3%+3.9%$1.85B$219.86M42.11490Positive NewsEYENational Vision2.5627 of 5 stars$22.69-0.8%$18.67-17.7%+91.0%$1.81B$1.82B-68.7613,411Positive NewsENOVEnovis3.3058 of 5 stars$30.01-0.3%$58.00+93.3%-25.6%$1.72B$2.11B-2.157,367News CoverageCNMDCONMED4.6114 of 5 stars$51.72-0.9%$62.20+20.3%-19.3%$1.61B$1.31B13.613,900TNDMTandem Diabetes Care4.2968 of 5 stars$20.22flat$33.43+65.3%-56.3%$1.35B$940.20M-7.272,650Positive NewsSSIISS Innovations InternationalN/A$5.65-18.4%N/AN/A$1.34B$22.13M0.004Positive NewsGap UpCDRECadre3.6586 of 5 stars$32.76-0.3%$37.50+14.5%-3.9%$1.34B$567.56M34.482,284AORTArtivion2.6069 of 5 stars$30.84+1.9%$32.00+3.8%+20.7%$1.29B$388.54M-61.671,600Positive NewsLQDALiquidia Technologies3.3761 of 5 stars$13.26+0.7%$26.89+102.8%-0.3%$1.13B$14M-8.3950 Related Companies and Tools Related Companies NovoCure Alternatives LeMaitre Vascular Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives Tandem Diabetes Care Alternatives SS Innovations International Alternatives Cadre Alternatives Artivion Alternatives Liquidia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
